The BIOSECURE Act did not arrive with ceremony. It arrived embedded in the National Defense Authorization Act, debated largely in abstractions, and passed with little public attention. But for pharmaceutical and biotechnology companies operating global […]

The pharmaceutical landscape is evolving rapidly, and one of the most transformative shifts is the rise of direct-to-patient (D2P) distribution. As manufacturers seek to bypass traditional channels and deliver medications straight to patients’ doors, the […]